A book review with some notes on my recent research, part I Introduction I have stated before that I believe that the field of psychiatry...

Introduction For some time now, INmune Bio has been announcing their trial in treatment resistant depression (TRD). The market, either...

Summary: · The detrimental action of glia, mostly microglia, in the inflamed brain is the last piece of the scientific puzzle; · ...

The 7 April 2022 CMS decision denying Aduhelm medicare coverage On 7 April 2022, the Centers for Medicare and Medicaid Services (CMS)...

"I think a good drug might fail in a clinical trial because not all the subjects have the same kind of Alzheimer's. Shubhabrata...

Introduction CJ Barnum, head of neuroscience at INMB, has a talent for translating his superior scientific knowledge to a crowd. The...

Introduction Apart from the abundant preclinical data showing efficacy in animals, XPro has been tested in six patients in the Phase 1...

What is neurofilament-light chain (NfL)? Neurofilaments, the larger group to which NfL belongs, are structural components of neuronal...

A small recap of existing drugs approved for AD There are four FDA-approved drugs for Alzheimer’s disease, three of which are...

What most investors seem to forget is diving into scientific literature The trials and tribulations of the stock market seem, to me, in...

Reminder of the NK cell activation threshold as a predictor of survival This, we know. · INKmune generates memory-like NK cells in...

Summary: INKmune is an NK-targeting immuno-oncology drug allowing treatment in a wide range of NK-related cancers; INKmune’s production...

In my mind's eye, these stairs keep on going into 2023 and the years after. INTRODUCTION The previous five blogs have laid out the...

My views on possible partnership/buyout and valuation of INMB will be set out below. The highlights are the following. - I consider a...

The immuno-oncology platform INKmune of INmune Bio may be a better, easier to produce and cheaper product candidate than others.

INTRODUCTION As an immunotherapy drug candidate, INKmune seems by far the most commercially sustainable, undervalued that I am aware of....

Drug XPro of INmune Bio has limitless potential in neurodegenerative diseases such as Alzheimers, ALS, MS, Huntington's, Parkinson's, ...

Introduction I believe INmune Bio, a company with a market cap of just 200 million dollars at the time of writing, will end up being...